The Indian government may be upping the ante for drug makers who fail to follow new guidelines by doubling the penalties it imposes when manufacturing plants attract the ire of international regulators, according to a report in The Hindustan Times.
Myanmar is trying to kick-start its pharmaceutical manufacturing industry to wean itself off foreign imports, according to a recent report on the Frontier Myanmar news website.
Indian pharmaceutical firms got some good news last week when it was reported that during the period from July to September there was a 50% gain in the number of abbreviated new drug approvals (ANDAs) by the U.S. FDA, Bloomberg TV India reported.
Indian drug manufacturers are working to combine drugs used to treat hepatitis C in ways not possible in the West because of patent restrictions, according to a Bloomberg News report.
Dilip Shah, secretary-general of the Indian Pharmaceutical Alliance, said this week's decision by the Delhi High Court against homegrown Glenmark Pharmaceuticals showed "due process was followed" and that Indian companies could not count on Indian courts for special treatment, according to a report in the Wall Street Journal.
China oncology biotech BeiGene has snapped up Changzhen Wu to head a manufacturing operation that is in the process of outfitting a major facility in Suzhou, building on another key hire snatched from WuXi AppTec to build out a formidable team.
A nonprofit plans to address drug shortages in the U.S. by making its own products under a model that seeks to break a chain of manufacturing quality and price concerns that also have the sharp attention of regulators and policymakers.
Taiwan's JHL Biotech said its listing of an unspecified number of shares on the Taiwan Emerging Stock Board this week has clocked in a value of NTD$1.89 billion ($57.6 million) as it ramps up services in the manufacture and development of biologics in Asia ahead of a potential main board listing.
India may house drug testing laboratories in each state under an INR17.5 billion ($270 million) plan to shore up quality.
India wants to cap drug prices at home while ramping up sales of generics to Western markets targeting the U.S.--all while dozens of manufacturing plants are under regulatory scanners on quality and testing.